Compare JPMorgan Chase & Co (JPM) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Zoetis Inc — how do they compare? JPMorgan Chase & Co trades at $362.27 (market cap $962.37B), while Zoetis Inc trades at $73.65 (market cap $31.14B). The key difference: JPMorgan Chase & Co is far larger — about 30.9× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| JPM | ZTS | |
|---|---|---|
Market Cap | $962.37B | $31.14B |
Volume | 10,479,943 | — |
Sector | Financials | Health |
52-Week High | $362.04 | $156.76 |
52-Week Low | $282.84 | $71.91 |
Dividend Yield | 1.66% | 2.81% |
Enterprise Value | — | $38.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase & Co. (JPM) trades at $365.63, up 1.62% today, with a bullish technical outlook and strong fundamentals. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth from $181.85B in 2025 to an estimated $194.9B in 2026. The stock shows robust profitability with a net income margin of 33.38% and ROE of 18.43%, supported by a moderate P/E of 15.51. Analyst consensus is a 'Moderate Buy' with a $374.18 price target, indicating potential upside amid positive sentiment.
JPM offers a solid investment case driven by earnings growth and sector leadership, but faces risks from macroeconomic volatility and geopolitical tensions. The stock's current price near resistance at $366 requires monitoring for breakout potential, while institutional accumulation and CEO insights on economic risks highlight both opportunity and caution for investors.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
